Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Combotox |
Synonyms | |
Therapy Description |
Combotox is an immunotoxin preparation that consists of an equal mixture of CD19 and CD22 monoclonal antibodies each conjugated to deglycosylated ricin A chain, which potentially induces cytotoxicity against tumor cells (PMID: 21732928). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Combotox | IgG-HD37-dgA/IgG-RFB4-dgA|deglycosylated ricin A chain CD19/CD22 immunotoxin | CD19 Antibody 21 | Combotox is an immunotoxin preparation that consists of an equal mixture of CD19 and CD22 monoclonal antibodies each conjugated to deglycosylated ricin A chain, which potentially induces cytotoxicity against tumor cells (PMID: 21732928). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT00450944 | Phase I | Combotox | Anti-CD19 and Anti-CD22 Immunotoxins in Treating Patients With Refractory or Relapsed B-Cell Acute Lymphoblastic Leukemia | Completed | USA | 0 |